P005 Diagnosis and Management of Cutaneous Lymphomas: Cases from Multidisciplinary Clinics for the General Derm
DESCRIPTION
In this session, cutaneous lymphoma experts will use real-life cases from their multidisciplinary cutaneous lymphoma clinics to illustrate best practices for diagnosing and managing cutaneous B-cell and cutaneous T-cell lymphoma. Emphasis will be placed on practical tips, including:
- How T-cell receptor gene rearrangements can help aid in diagnosis of CTCL
- How to stage a new patient with suspected CTCL or CBCL
- Skin-directed therapies for CTCL, including how to prescribe topical nitrogen mustard
- Management of pain and pruritus associated with CTCL
- Treatments for advanced CTCL, and when to refer to an oncologist
- Non-MF/SS CTCLs, including CD30+ lymphoproliferative disorders
LEARNING OBJECTIVES
Identify some of the most common and “don’t miss” subtypes of cutaneous lymphoma seen by the general dermatologist.
Discuss strategies for accurate diagnoses of cutaneous lymphomas, including the use of molecular techniques (flow cytometry and clonality).
Outline a treatment strategy for early stage and for advanced stage CTCL.
SCHEDULE
3:00 PM
Diagnosing and staging a new patient with CTCL or CBCL
Shamir S. Geller, MD, IFAAD
3:22 PM
Treatment of early CTCL
Jina Chung, MD, FAAD
3:44 PM
Management of pain and pruritus in cutaneous lymphoma
Cecilia Larocca, MD, FAAD
4:06 PM
Treatment of advanced CTCL
Christiane Querfeld, MD, PhD, FAAD
4:28 PM
Non MF/SS-CTCL, including CD30+ lymphoproliferative disorders
Joan Guitart, MD, FAAD
4:50 PM
Q&A
SPEAKERS
Jina Chung, MD, FAAD
Shamir S. Geller, MD, IFAAD
Memorial Sloan Kettering Cancer Center
Joan Guitart, MD, FAAD
Cecilia Larocca, MD, FAAD
Christiane Querfeld, MD, PhD, FAAD
City of Hope and Beckman Research Institute
SPEAKER DISCLOSURES
Jina Chung, MD, FAAD
No financial relationships exist with ineligible companies.
Shamir S. Geller, MD, IFAAD
No financial relationships exist with ineligible companies.
Joan Guitart, MD, FAAD
Castle Biosciences – Consultant (1099 relationship)(Fees); Kyowa Hakko Kirin Pharma, Inc. – Consultant(Honoraria);
Cecilia Larocca, MD, FAAD
No financial relationships exist with ineligible companies.
Christiane Querfeld, MD, PhD, FAAD
Citius Pharmaceuticals – Advisory Board(Honoraria); Helsinn Healthcare – Advisory Board(Honoraria); Kyowa Hakko Kirin Pharma, Inc. – Investigator(Fees), Investigator(Grants/Research Funding); Kyowa Kirin – Advisory Board(Honoraria); Mallinckrodt Pharmaceuticals – Advisory Board(Honoraria);